Dr Robert Garnick joins Peregrine
This article was originally published in Scrip
Peregrine Pharmaceuticals (US) has named Dr Robert Garnick head of regulatory affairs. He will be responsible for overseeing Peregrine's interactions with the US FDA and global regulatory agencies, and will lead the development of regulatory strategies for advancing the company's monoclonal antibody-based treatments for cancer and infectious diseases. Dr Garnick was formerly senior vice-president of regulatory, quality and compliance at Genentech.